RAPPORT THERAPEUTICS INC (RAPP) Stock Fundamental Analysis

NASDAQ:RAPP • US75383L1026

30.2 USD
+1.21 (+4.17%)
At close: Feb 25, 2026
32 USD
+1.8 (+5.96%)
After Hours: 2/25/2026, 4:30:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, RAPP scores 3 out of 10 in our fundamental rating. RAPP was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for RAPP as it has an excellent financial health rating, but there are worries on the profitability. RAPP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • RAPP had negative earnings in the past year.
  • In the past year RAPP has reported a negative cash flow from operations.
RAPP Yearly Net Income VS EBIT VS OCF VS FCFRAPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • RAPP's Return On Assets of -18.25% is fine compared to the rest of the industry. RAPP outperforms 63.02% of its industry peers.
  • RAPP has a better Return On Equity (-19.10%) than 69.79% of its industry peers.
Industry RankSector Rank
ROA -18.25%
ROE -19.1%
ROIC N/A
ROA(3y)-26.98%
ROA(5y)N/A
ROE(3y)-34.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RAPP Yearly ROA, ROE, ROICRAPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • RAPP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPP Yearly Profit, Operating, Gross MarginsRAPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • RAPP has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for RAPP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RAPP Yearly Shares OutstandingRAPP Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
RAPP Yearly Total Debt VS Total AssetsRAPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 34.90 indicates that RAPP is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of RAPP (34.90) is better than 94.27% of its industry peers.
  • There is no outstanding debt for RAPP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.9
ROIC/WACCN/A
WACCN/A
RAPP Yearly LT Debt VS Equity VS FCFRAPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 36.37 indicates that RAPP has no problem at all paying its short term obligations.
  • RAPP has a better Current ratio (36.37) than 97.40% of its industry peers.
  • RAPP has a Quick Ratio of 36.37. This indicates that RAPP is financially healthy and has no problem in meeting its short term obligations.
  • RAPP has a better Quick ratio (36.37) than 97.40% of its industry peers.
Industry RankSector Rank
Current Ratio 36.37
Quick Ratio 36.37
RAPP Yearly Current Assets VS Current LiabilitesRAPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • RAPP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.35%.
EPS 1Y (TTM)-3.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.60% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.6%
EPS Next 2Y2.26%
EPS Next 3Y-3.14%
EPS Next 5Y-1.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPP Yearly Revenue VS EstimatesRAPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
RAPP Yearly EPS VS EstimatesRAPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • RAPP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RAPP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPP Price Earnings VS Forward Price EarningsRAPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPP Per share dataRAPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • RAPP's earnings are expected to decrease with -3.14% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.26%
EPS Next 3Y-3.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RAPP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RAPPORT THERAPEUTICS INC

NASDAQ:RAPP (2/25/2026, 4:30:02 PM)

After market: 32 +1.8 (+5.96%)

30.2

+1.21 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-09
Inst Owners103.43%
Inst Owner Change0.52%
Ins Owners4.65%
Ins Owner Change-1.18%
Market Cap1.44B
Revenue(TTM)N/A
Net Income(TTM)-97.70M
Analysts85.33
Price Target53.3 (76.49%)
Short Float %7.3%
Short Ratio9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.91%
Min EPS beat(2)10.23%
Max EPS beat(2)11.59%
EPS beat(4)4
Avg EPS beat(4)11.17%
Min EPS beat(4)10.23%
Max EPS beat(4)12.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.23%
EPS NY rev (1m)0.08%
EPS NY rev (3m)6.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-2.71
EYN/A
EPS(NY)-3.6
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0
BVpS10.73
TBVpS10.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.25%
ROE -19.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.98%
ROA(5y)N/A
ROE(3y)-34.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.37
Quick Ratio 36.37
Altman-Z 34.9
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1213.57%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42%
EPS Next Y23.6%
EPS Next 2Y2.26%
EPS Next 3Y-3.14%
EPS Next 5Y-1.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.51%
EBIT Next 3Y-30.84%
EBIT Next 5YN/A
FCF growth 1Y-133.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.5%
OCF growth 3YN/A
OCF growth 5YN/A

RAPPORT THERAPEUTICS INC / RAPP FAQ

What is the fundamental rating for RAPP stock?

ChartMill assigns a fundamental rating of 3 / 10 to RAPP.


What is the valuation status for RAPP stock?

ChartMill assigns a valuation rating of 0 / 10 to RAPPORT THERAPEUTICS INC (RAPP). This can be considered as Overvalued.


What is the profitability of RAPP stock?

RAPPORT THERAPEUTICS INC (RAPP) has a profitability rating of 1 / 10.


What is the financial health of RAPPORT THERAPEUTICS INC (RAPP) stock?

The financial health rating of RAPPORT THERAPEUTICS INC (RAPP) is 8 / 10.